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Purpose: There is no consensus on how to treat high-risk prostate cancer, and long-term results from hypofractionated radiation therapy
are lacking. We report 10-year results after image guided, intensity modulated radiation therapy with hypofractionated simultaneous
integrated boost and elective pelvic field.
Methods and Materials: Between 2007 and 2009, 97 consecutive patients with high-risk prostate cancer were included, treated with 2.7
to 2.0 Gy  25 Gy to the prostate, seminal vesicles, and elective pelvic field. Toxicity was scored according to Radiation Therapy
Oncology Group criteria and biochemical disease-free survival (BFS) defined by the Phoenix definition. Patients were subsequently
divided into 3 groups: high risk (HR; n Z 32), very high risk (VHR; n Z 50), and Nþ/seprostate-specific antigen (PSA) 100 (n Z
15). Differences in outcomes were examined using Kaplan-Meier analyses.
Results: BFS in the patients at HR and VHR was 64%, metastasis-free survival 80%, prostate cancer-specific survival 90%, and overall
survival (OS) 72%. VHR versus HR subgroups demonstrated significantly different BFS, 54% versus 79% (P Z .01). Metastasis-free
survival and prostate cancer-specific survival in the VHR group versus HR group were 76% versus 87% (P Z .108) and 74% versusSources of support: Supported by an independent, no-restriction grant to Dr Olav Dahl from Trond Mohn Foundation.
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Advances in Radiation Oncology: MayeJune 2020 Hypofractionation with SIB in prostate cancer 397100% (P Z .157). Patients reaching nadir PSA <0.1 (n Z 80) had significantly better outcomes than the rest (n Z 17), with BFS 70%
versus 7% (P < .001). Acute grade 2 gastrointestinal tract (GI) and genitourinary tract (GU) toxicity occurred in 27% and 40%, grade 3
GI and GU toxicity in 1% and 3%. Late GI and GU grade 2 toxicity occurred in 1% and 8%.
Conclusions: High-risk prostate cancer patients obtained favorable 10-year outcomes with low toxicity. There were significantly better
results in the HR versus the VHR group, both better than the Nþ/PSA 100 group. A nadir PSA value < 0.1 predicted good prognosis.
 2019 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer is the most common malignancy and
the second leading cause of cancer mortality in Norwe-
gian men. Although beneficial results are obtained when
treating low- and intermediate-risk tumors by most
treatment modalities, high-risk disease still represents a
major challenge.1 There are no randomized controlled
trials comparing radiation therapy versus prostatectomy,
and there is no consensus regarding optimal management.
According to guidelines, standard treatment is intensity
modulated radiation therapy (IMRT) combined with long-
term androgen deprivation therapy (ADT) or prostatec-
tomy with extended pelvic lymph node dissection.1
Dose-escalation improves relapse-free survival in
prostate cancer,2,3 and in intermediate- or high-risk dis-
ease, there is also evidence of an overall survival benefit.4
Because the a/b ratio for prostate cancer is considered to
be low, in the range of 1.1 to 1.7 Gy,5,6 hypofractionation
may improve local control. With the publication of 4 large
phase III studies on moderate hypofractionation, it is now
considered safe and effective,7-12 and guidelines from the
American Society for Radiation Oncology (ASTRO),
American Society of Clinical Oncology (ASCO), and
American Urological Association (AUA) state that mod-
erate hypofractionation should be offered to low-risk,
intermediate-risk, and high-risk localized prostate cancer
candidates for external beam radiotherapy (EBRT).13
However, with the exception of a subset of patients in
the Fox Chase trial,14 none of the studies referred to by
the guidelines included radiation of an elective pelvic
nodal field, and long-term efficacy data beyond 5 years
are still lacking.
The role of whole pelvic radiation therapy (WPRT) is
controversial. It has been advocated for in patients with
high estimated probability of spread to the regional nodes
based on pre-treatment nomograms, but no randomized
trial has shown a clear advantage compared with radiation
to the prostate only. Hence, the question of WPRT still
remains unresolved.15
There is great disease heterogeneity within the high-
risk group,16 and studies using surgery have shown dif-
ferences in outcome. Patients who meet very high-risk
(VHR) criteria (primary Gleason pattern 5 present on
biopsy, 5 cores with Gleason sum 8 to10, or 2 high-risk factors) have particularly poor oncologic out-
comes.17-19 It is not clear whether these criteria also apply
to men treated with EBRT.20,21
Our department has a long tradition of dose-escalation
and WPRT.22 In the present study, we report 10-year
results from a prospective phase II protocol of pelvic ra-
diation therapy using image guided IMRT with WPRT
and hypofractionated simultaneous integrated boost (SIB)
to the prostate in high-risk prostate cancer.
Methods and Materials
From June 2007 to February 2009, we included 97
consecutive patients with adenocarcinoma of the prostate
referred to Haukeland University Hospital for EBRT.
Patients with T3-4 tumors, risk of lymph node metastasis
>15% according to Roach equation,23 or positive lymph
nodes detected by surgical staging were considered
eligible. Lymph node sampling was not mandatory and
performed in 18 patients. T-staging was mainly done by
digital rectal examination. Bone scan (scintigraphy or
skeletal magnetic resonance imaging [MRI]) was obtained
in patients with seprostate-specific antigen (PSA) >10
ng/mL or Gleason score >7, and a diagnostic abdominal
and pelvic computed tomographic (CT) scan was per-
formed in patients with s-PSA >50 ng/mL. All patients
had 3 fiducial markers implanted in the prostate at least 1
week before radiation therapy. The study protocol was
approved by the Regional Ethical Committee (REK 2006/
15727), and a written informed consent was obtained
from each patient before enrollment.
Patient characteristics are presented in Table 1. All
patients had high-risk cancers defined as clinical stage
T3, Gleason score 8, or s-PSA >20 ng/mL. Median
age was 66 years (range, 46-79 years) and median s-PSA
was 20 (range, 5-128; mean, 30). Median follow-up was
121 months (range, 15-148) for all patients and 124
months (range, 113-148) for surviving patients. Clinical
stage was T3a in 79 patients, and Gleason score was 8
in 37 patients. Patients were subsequently divided into 3
different groups. Based on the 2015 National Compre-
hensive Cancer Network (NCCN) VHR criteria and re-
sults from studies on surgery and EBRT,17-21,24 we
formed a VHR group consisting of patients with primary
Gleason pattern 5 present on biopsy, 5 cores with
Table 1 Patient characteristics by risk group
Characteristic Regular high-risk N Z 32 Very
high-risk N Z 50
Nþ/PSA 100 N Z 15 Total N Z 97
Age, median (range), y 67 (55-76) 65 (47-79) 62 (46-71) 66 (46-79)
Clinical T-stage
T1 0 1 0 1
T2 6 7 4 17
T3 25 41 11 77
T4 1 1 0 2
Grade group (Gleason pattern)
Grade group 1 (3 þ 3) 2 4 1 7
Grade group 2 (3 þ 4) 17 7 1 25
Grade group 3 (4 þ 3) 12 11 5 28
Grade group 4 (4 þ 4) 0 16 5 21
Grade group 5 (score 9-10) 1 12 3 16
Pretreatment s-PSA, ng/mL
<10 8 4 1 13
10-19 19 9 3 31
20-39 3 25 3 31
40-99 2 12 3 17
100 0 0 5 5
Abbreviation: PSA Z prostate-specific antigen.
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The second group consisted of high-risk patients (HR)
without VHR characteristics (n Z 32). Patients with
metastases to pelvic lymph nodes (Nþ; n Z 11) or pre-
treatment s-PSA 100 (n Z 5) were allocated to the third
group (n Z 15). Ten of the Nþ patients had positive
lymph nodes detected by lymph node sampling, and one
had pathologically enlarged pelvic lymph nodes on MRI
before initiation of ADT. Patients with suspicious but not
enlarged lymph nodes were considered as lymph node
negative.
The treatment procedure has been presented in detail
elsewhere,25 but will be briefly described. Three clinical
target volumes (CTV) were defined receiving different
dose levels, with the higher dose levels administered as
SIB.
1. CTV67.5: prostate. Dose 2.7 Gy  25 Z 67.5 Gy
(equivalent to 81.2 Gy in 2 Gy fractions).
2. CTV60: prostate and seminal vesicles. Dose: 2.4 Gy
 25 Z 60 Gy (equivalent to 67.5 Gy in 2 Gy
fractions).
3. CTV50: prostate and seminal vesicles and pelvic
lymph nodes. Dose: 2 Gy  25 Z 50 Gy.
Radiation therapy was administered according to the
plan in 96 patients. One patient stopped after 23 fractions
owing to acute grade 3 GI toxicity. No additional boost to
lymph nodes was given to the Nþ patients as there were
no enlarged lymph nodes at CT for dose planning. All
patients received luteinizing hormone-releasing hormone
analogs 3 months before initiation of radiation therapy
with an intended total duration of 2 years, and with theaddition of an antiandrogen the first 4 weeks to prevent a
tumor flare.
The primary endpoints were BFS, metastasis free sur-
vival (MFS), and prostate cancer-specific survival (PCSS).
Secondary endpoints were peak Radiation Therapy
Oncology Group (RTOG) acute and late genitourinary tract
(GU) and gastrointestinal tract (GI) a toxicity.26 Addition-
ally, we evaluated whether a detectable nadir PSA (nPSA),
defined as the lowest PSA level after treatment that was
0.1 ng/mL, could predict an increased risk of recurrence.
Follow-up assessments were performed 2 to 3 times during
radiation therapy, and acute toxicity was scored using
RTOG criteria during the last week of radiation therapy and
at 3 months. Follow-up assessments were thereafter per-
formed every third month up to 2 years after radiation
therapy, later every sixth month up to 5 years. After 5 years,
patients were followed once a year. Biochemical recurrence
was defined according to Phoenix criteria (nPSA þ 2 ng/
mL).27 Local recurrence was defined as biopsy confirmed
local recurrence after radiation therapy, or radiologic find-
ings on MRI.28
Statistical analyses were performed using SPSS sta-
tistics (IBM Corp, Armonk, NY, version 25). To assess
survival outcomes for BFS, MFS, PCSS, and OS, Kaplan-
Meier estimates were calculated, and differences were
assessed by the log-rank test.Results
At median follow-up of 10.1 years, Kaplan-Meier es-
timate of BFS for the entire cohort was 59% (95% con-
fidence interval, 48%-70%), and MFS was 74% (95% CI,
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disease was to bone (n Z 18). No metastases to lymph
nodes in the irradiated area were observed. All clinical
recurrences followed a biochemical recurrence. Ten-year
PCSS and OS was 87% (95% CI, 80%-94%) and 70%
(95% CI, 61%-79%), respectively. Causes of death other
than prostate cancer were other cancers (n Z 6); in-
fections (n Z 2); cardiovascular (n Z 3); Parkinson
disease, Alzheimer disease, or dementia (n Z 4); liver
failure (n Z 1); and unknown (n Z 1). Local recurrence
was observed in 11 patients (Table 2). Two of them later
developed distant metastasis. Five patients had biochem-
ical recurrence only (Table 2).
Median time to biochemical recurrence was 50 months
(range, 9-106) among those with recurrence. The systemic
recurrences occurred at median 39 months (range, 9-81),
and the local recurrences occurred later, at median 73
months (range, 40-106).
In the 82 HRþVHR patients 10- year BFS was 64%
(95% CI, 53%-75%), MFS 80% (95% CI, 71%-89%),
PCSS 90% (95% CI, 83%-97%), and OS 72% (95% CI,
62%-82%).
We observed a significant difference in BFS across the
risk groups (Fig 1). BFS was 79%, 54%, and 29% in the
HR, VHR, and Nþ/PSA 100 groups, respectively (P <
.001). There was a nonsignificantly different MFS and
PCSS in the patients at HR compared with the patients at
VHR, 87% versus 76% (P Z .1) and 100% versus 84%
(P Z .16), respectively. The patients in the Nþ/PSA
100 group had significantly worse MFS and PCSS than
the patients at VHR/HR, 39% versus 80% (P < .001) and
71% versus 90% (P Z .04). There was no difference in
OS in the respective groups; 75% in HR, 70% in VHR,
and 60% in Nþ/PSA 100 patients (P Z .591). PCSS
and OS for the 3 groups are shown in Figure E1 (available
online at https://doi.org/10.1016/j.adro.2019.11.007).
Of the 11 patients with lymph node positive disease, 7
had recurrence, all with metastases. Three patients were
alive without any signs of recurrence after 10 years, and
one died while still in remission (Table 2). Four out of 5
patients with pretreatment s-PSA 100 were still alive at
10-year follow-up, and 1 died of other causes. All 4 had a
biochemical recurrence, but none were in a castration
refractory phase at the last follow-up.Table 2 Recurrence and cause of death by risk group (%)
Regular high-risk
N Z 32 (%)
V
N
Biochemical recurrence only 1 (3)
Local recurrence 2 (6)
Metastasis 3 (9) 1
Death from prostate cancer 1 (3)
Death from other causes 8 (25)
Abbreviation: PSA Z prostate-specific antigen.The rate of patients reaching a nPSA <0.1 was equal
in the HR and VHR groups (88%), in the Nþ/PSA 100
group the rate was 53%. Outcomes were significantly
better in patients reaching nPSA <0.1 (nZ 80) compared
with the rest (n Z 17). Ten-year BFS was 70% versus 7%
(P < .001), MFS 86% versus 15% (P < .001), PCSS 89%
versus 61% (P Z .001), and OS 72% versus 43% (P Z
.005), respectively. BFS stratified by nPSA in the entire
cohort of 97 patients is shown in Fig 2.
BFS according to the new International Society of
Urological Pathology grade group system29 is shown in
Fig E2 (available online at https://doi.org/10.1016/j.
adro.2019.11.007). The 5-year BFS probabilities were
100%, 96%, 64%, 76%, and 40%, and 10-year BFS
probabilities were 100%, 77%, 48%, 61%, and 20%.
Notably, there was a significant difference between grade
group 2 and grade group 3 (P Z .03). The effect on BFS
by the different levels of pretreatment s-PSA is shown in
Fig E3 (available online at https://doi.org/10.1016/j.
adro.2019.11.007).
Data on acute toxicity was complete in all patients; 3
patients missed data on late toxicity. The peak RTOG
acute GI and GU score was grade 2 in 27% and 40%,
respectively, and acute grade 3 GI and GU toxicity was
observed in 1% and 3% (Table 3).
A peak late RTOG GI and GU grade 2 occurred in 1%
and 8%, and only one patient experienced late grade 3 GU
toxicity.
The scheduled 24 months of ADT was completed in
54%. More patients completed ADT in the Nþ/PSA
100 group (82%) compared with the regular HR and
VHR group (47% and 50%). The reason for terminating
ADT was in all cases intolerable side effects. We found
no association between early termination of ADT and
BFS (data not shown).Discussion
To date there are limited published outcomes beyond 5
years for moderate hypofractionation in prostate cancer,
and biochemical measures of cancer control predominate
in studies. The present prospective study shows favorable
long-term oncologic outcomes of importance such asery high-risk
Z 50 (%)
Nþ/PSA 100
N Z 15 (%)
Total
N Z 97 (%)
3 (6) 1 (7) 5 (5)
7 (14) 2 (13) 11 (11)
1 (22) 8 (53) 22 (23)
7 (14) 4 (27) 12 (12)
8 (16) 2 (13) 18 (19)
Figure 1 Biochemical disease-free survival by the different risk groups. Abbreviation: PSA Z prostate-specific antigen.
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heterogeneity within the high-risk population. The results
compare favorably with other trials on surgery or EBRT
combined with ADT. In the study from Johns Hopkins
radical prostatectomy database, which used the same
VHR definition as in our study, 10-year BFS was 21%,
MFS 37%, and PCSS 62% in the VHR population
compared with 41%, 78%, and 90% in other high-risk
men.17 A study on radiation therapy demonstrated 10-year
BFS 46%, MFS 65%, and PCSS 82% in the VHR group
compared with 65%, 87%, and 94% in other high-risk
men.20 A recent published study on moderately hypo-
fractionated radiation therapy demonstrated 10-year BFSFigure 2 Biochemical disease-free survival by nadir prostate-speci
specific antigen.of 42% in the general high-risk population.30 In the pre-
sent study, 10-year BFS was 54%, MFS 76%, and PCSS
84% in the VHR population compared with 79%, 87%,
and 100% in the HR group.
The proportion of VHR and Nþ/PSA 100 patients
was large in the present study: 52% and 15%, respec-
tively. This reflects the unselected population of patients
treated with EBRT in our institution. The proportion is
larger compared with studies on radical prostatectomy; in
the Johns Hopkins radical prostatectomy database, the
proportion of VHR patients was 15.1%,17 and in the study
from Lee et al, 56.5% had only one high-risk factor.19
Heterogeneity in risk factors and comorbidities withinfic antigen in the entire cohort. Abbreviation: PSA Z prostate-
Table 3 Acute and late toxicity





Grade 0 15 69 9 42
Grade 1 55 27 47 45
Grade 2 26 1 40 8
Grade 3 1 - 3 1
Grade 4 - - - -
Abbreviations: GI Z gastrointestinal tract; GU Z genitourinary
tract.
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compare outcomes from different treatment modalities; a
smaller amount of VHR patients will lead to better cancer
related outcomes, and differences in comorbidities have a
large effect on OS in older men.
Patients with s-PSA 100 are frequently excluded
from studies on radical treatment because they are
considered having a high probability of systemic dis-
ease.31 Although 4 out of 5 patients with pretreatment
s-PSA 100 in our study had recurrence, there were no
deaths from prostate cancer at 10-year follow-up. It is not
clear whether the combined EBRT and ADT contributed
to a more favorable outcome compared with the alterna-
tive lifelong treatment with ADT. However, during the
past years there has been a growing interest in local
therapy to patients with advanced and metastatic disease,
culminating with the STAMPEDE (Systemic Therapy in
Advancing or Metastatic Prostate Cancer: Evaluation of
Drug Efficacy) trial which demonstrated an overall sur-
vival benefit treating the primary tumor with EBRT in
patients with newly diagnosed metastatic prostate cancer
and a low metastatic burden.32
There are no randomized trials establishing the role of
radical therapy in men with clinically evident lymph
nodes, and there is uncertainty regarding optimal treat-
ment. In the inclusion period, metastasis to pelvic lymph
nodes (Nþ) was considered a systemic disease state,33
and the American Joint Committee on Cancer still clas-
sifies patients with Nþ as having stage IV disease. The 11
Nþ patients in our cohort did have the poorest outcomes.
However, 4 patients had no signs of recurrence, and 3
patients were alive without signs of recurrence at 10
years. Patients with metastasis to pelvic lymph nodes
should therefore not be omitted from radical treatment.
A low nPSA value is previously demonstrated to be a
strong independent predictor of BFS after EBRT in in-
termediate and high-risk disease.34 Our study demon-
strates significantly better outcomes for all cancer related
endpoints when nPSA <0.1 is reached after therapy. The
nPSA level could therefore potentially be used in future
selection of patients for a more frequent follow-up or
inclusion in studies on adjuvant treatment.Tolerance to treatment was excellent, and the fre-
quencies of durable grade 2 and 3 GU and GI side effects
were low and similar to the recent studies on hypo-
fractionation and other studies using image guided radi-
ation therapy to high dose.7,10,12,35,36 Importantly, the
addition of an elective pelvic field (to 50 Gy) did not
increase long-term toxicity.
The main strengths of the study are the prospective
study design and the long follow-up time. A follow-up
time beyond 5 years is critical when analyzing long-term
endpoints such as PCSM and local recurrence. Although
patients were enrolled between 2007 and 2009, treatment
technique with image guided IMRT, dose-escalation,
hypofractionation, and simultaneous boost is up to date
according to guidelines. Absence of a central pathology
evaluation is a study limitation. Reports on tolerance were
based on physician reports rather than from patient re-
ported data. Hence, there was a risk of underreporting
toxicity.
Patients with locally persistent prostate cancer are at
greater risk for distant metastases.37,38 Thus, the issue of
local control is important. There were 11 patients with
local recurrence in the total cohort. The low toxicity re-
ported suggests a chance of dose escalation to even higher
doses to achieve better local control, especially in patients
with VHR where local recurrence occurred in 14% (n Z
7) in our study. Further dose-escalation to intraprostatic
lesions by the use of MRI- guided boost is the topic of an
ongoing clinical trial in our department.
Conclusions
High-risk prostate cancer patients achieve favorable
long-term outcomes with low toxicity when treated with
pelvic image-guided IMRT with hypofractionated simul-
taneous integrated boost. Stratification of high-risk pa-
tients into HR and VHR subgroups demonstrated
significant effect on BFS and can be used in the decision
of which patients who may benefit from further dose-
escalation or multimodal treatment. A low nadir s-PSA
<0.1 was a strong predictor of better outcomes in the
high-risk population. The long time for recurrences to
appear demonstrates the importance of a long follow-up
in studies on combined radiation therapy and ADT.
Supplementary data
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2019.11.007.
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